News

Kiadis Pharma signs license agreement with Hospira to commercialize ATIR™ in Europe and Asia - Partnership would advance innovative stem cell transplant product 04-01-2011
Kiadis Pharma, a biopharmaceutical company based in The Netherlands, announced that it has entered into a licensing agreement with Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical company, to develop and commercialize Kiadis Pharma’s ATIR™. ATIR™ is a personalized hematology product... read more 

Kiadis Pharma receives IND approval from FDA to start pivotal clinical trial with ATIR™ 08-07-2010
Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR™ in the United States. Kiadis Pharma is currently... read more 

About us

Kiadis Pharma in brief

Kiadis Pharma is a biopharmaceutical company focused on complications and limitations of hematopoietic stem cell transplants (HSCT) in blood cancer patients. The company has three blood cancer products in clinical development that offer novel treatment options for terminally ill cancer patients addressing high-unmet medical needs. Kiadis Pharma is headquartered in Amsterdam, The Netherlands.

 

Kiadis Pharma has recently begun a registration study for ATIR™, the Company’s lead clinical program. Patients are being enrolled at clinical sites in various European countries as well as in Canada and the United States. For more information about enrolment in a clinical study of ATIR™, see www.clinicaltrials.gov

Kiadis Pharma

Entrada 231-234
1096 EG  Amsterdam
The Netherlands


T +31 (0)20 314 02 50
F +31 (0)20 314 02 51